People: Strategic Diagnostics Inc (SDIX.O)
SDIX.O on Consolidated Issue listed on NASDAQ Global Market
1.06USD
17 May 2013
1.06USD
17 May 2013
Price Change (% chg)
$0.02 (+1.92%)
$0.02 (+1.92%)
Prev Close
$1.04
$1.04
Open
$1.05
$1.05
Day's High
$1.07
$1.07
Day's Low
$1.05
$1.05
Volume
24,221
24,221
Avg. Vol
37,290
37,290
52-wk High
$1.85
$1.85
52-wk Low
$0.87
$0.87
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Thomas Bologna |
64 | 2011 | Independent Chairman of the Board |
Francis DiNuzzo |
56 | 2008 | President, Chief Executive Officer, Director |
Kevin Bratton |
63 | 2009 | Chief Financial Officer, Vice President - Finance, Corporate Secretary |
Steven Becker |
45 | 2008 | Independent Director |
C. Geoffrey Davis |
61 | 2007 | Independent Director |
Richard van den Broek |
47 | 2011 | Independent Director |
Stephen Waechter |
61 | 2002 | Independent Director |
David Wurzer |
53 | 2010 | Independent Director |
Wayne Yetter |
2010 | Independent Director |
Biographies
| Name | Description |
|---|---|
Thomas Bologna |
Mr. Thomas A. Bologna serves as an Independent Chairman of the Board of Strategic Diagnotics Inc., since February 2011. He joined the Company as a director in February 2010. Since December 2011, Mr. Bologna has been Chairman and CEO of Response Genetics, Inc., a diagnostics company. From 2006 through 2011, Mr. Bologna was President and Chief Executive Officer and a member of the Corporate Board of Directors of Orchid Cellmark, Inc., a international DNA testing company with its headquarters in Princeton, New Jersey. Prior to joining Orchid Cellmark, Inc., Mr. Bologna served as President, CEO and a director of Quorex Pharmaceuticals, Inc. Mr. Bologna also served as Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., President, CEO and a director of Scriptgen Pharmaceuticals, Inc. and Chairman of the Board, President and Chief Executive Officer of Gen-Probe Incorporated. Mr. Bologna also serves on the business advisory board of The Epilepsy Project. Mr. Bologna holds an MBA and Bachelor of Science degrees from New York University. |
Francis DiNuzzo |
Mr. Francis M. DiNuzzo serves as President, Chief Executive Officer, Director of Strategic Diagnotics Inc., since October 13, 2008. Mr. DiNuzzo joined the Company in February 2008 as Executive Vice President Marketing and Chief Commercial Officer. Prior to joining SDI, Mr. DiNuzzo spent 26 years at Agilent Technologies/Hewlett Packard. He began his career in research and development in 1981 and advanced through a series of functional management roles over the next 18 years. In 1999, Mr. DiNuzzo became General Manager of Agilent’s Chemical Solutions Business Unit where he had global responsibility for analytical equipment, consumables and service products serving the chemical, environmental, food and forensics markets. In 2001, Mr. DiNuzzo became General Manager of the Consumable and Services Business Unit, with global responsibility for all consumables and services across all Life Science and Chemical Analysis markets. In 2004, Mr. DiNuzzo became Vice President and General Manager of the Integrated Biology Solutions unit, a role where he formed a biotechnology business focused on Genomics, Proteomics and BioInformatics. Mr. DiNuzzo holds B.S and M.S. degrees in Engineering with a minor in Business Administration from the University of New Hampshire. Mr. DiNuzzo serves on the Board of Directors of Delaware Bioscience Association. |
Kevin Bratton |
Mr. Kevin J. Bratton serves as Chief Financial Officer, Vice President - Finance, Corporate Secretary of Strategic Diagnotics Inc. Mr. Bratton was Senior Vice President Business Operations for EUSA Pharma (USA), Inc. in Langhorne, Pennsylvania from May 2008 until May 2009. Mr. Bratton had been Senior Vice President and Chief Financial Officer of Cytogen Corporation in Princeton, New Jersey from November 2006 until its acquisition by EUSA Pharma, Inc. in May 2008. Mr. Bratton has over 35 years of experience in all phases of multi-national financial operations across the healthcare, biotechnology and technology industries, including developing strategic plans and annual budgets as well as financing negotiations and merger & acquisition transactions. Prior to joining Cytogen, Mr. Bratton was Chief Financial Officer at Metrologic Instruments, Inc., a global technology company, from July 2002 until November 2006, where he directed the company’s finance operations during a period of growth in sales, net income, cash flow from operations, and working capital. Previously, Mr. Bratton began his career with the public accounting firm Touche Ross & Co. (now Deloitte & Touche LLP). He has a bachelor of science in business and accounting from Northeastern University. |
Steven Becker |
Mr. Steven R. Becker serves as an Independent Director of Strategic Diagnotics Inc., since March 2008. Since 2004, Mr. Becker has served as the managing partner and founder of Becker Drapkin Management, a Dallas-based small cap investment fund. Prior to founding Becker Drapkin, Mr. Becker was a partner at the Special Situations Funds, a New York City-based asset manager. Mr. Becker joined Special Situations in April 1997 and ran the Special Situations Private Equity Fund since its inception. Prior to joining Special Situations, Mr. Becker was a part of the distressed debt and leveraged equities research team at Bankers Trust Securities. He began his career at Manley Fuller Asset Management in New York as a small cap analyst. Mr. Becker currently serves as a director of Hot Topic, a publicly traded teen retailer, and Ruby Tuesday, Inc., a publicly traded company that owns, operates and franchises restaurants. Mr. Becker received a B.A. from Middlebury College and a J.D. from the University of Florida. |
C. Geoffrey Davis |
Dr. C. Geoffrey Davis, Ph.D., serves as an Independent Director of Strategic Diagnotics Inc., since September 2007. Currently, Dr. Davis is the CEO and Chairman and a director of Angelica Therapeutics, Inc., a privately held biotechnology company. In 1996, Dr. Davis founded Abgenix, Inc. in Fremont, California, where he served as the Chief Scientific Officer and led the development of the XenoMouse® technology and was involved in the research and development of Vectibix®, a fully human monoclonal antibody approved for the treatment of colorectal cancer. Dr. Davis also guided the discovery of 11 other antibodies currently in clinical trials. Abgenix was acquired by Amgen in early 2006. Prior to founding Abgenix, Dr. Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corp. and Cell Genesys, Inc. Dr. Davis received his Ph.D. in immunology from the University of California, San Francisco and completed his postdoctoral work at Southwestern University. He is the author of 37 publications and is an inventor on 11 issued patents. Mr. Davis serves as a director of Harbour Antibodies, AB and of Moerae Matrix. |
Richard van den Broek |
Mr. Richard van den Broek serves as an Independent Director of Strategic Diagnostics Inc. He joined the Company as a director in March 2008. Since 2004, Mr. van den Broek has been Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry. From 2000-2003 he was a Partner at Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to that Mr. van den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist. He serves as a director of Pharmacyclics, a drug development company, Response Genetics, a diagnostics company and Pharmaxis (an Australian public company). Mr. van den Broek is a graduate of Harvard University and is a Chartered Financial Analyst. |
Stephen Waechter |
Mr. Stephen L. Waechter serves as an Independent Director of Strategic Diagnotics Inc., since 2002. In June 2008, Mr. Waechter was appointed Chief Financial Officer and Vice President of Business Operations for Aeronautical Radio, Inc. Mr. Waechter served as Executive Vice President, Chief Financial Officer and Treasurer of CACI International Inc, a provider of information technology services and solutions, from April 1999 through 2007. From 1997 to 1999, he served as Executive Vice President, Chief Financial Officer and Treasurer of GTSI, Corp., a provider of integrated information technology solutions. Mr. Waechter serves as a director for NCI Information Systems, Inc. and Social and Scientific Services, Inc. He holds a B.A. in History from Christian Brothers College and received an M.B.A. from Xavier University. |
David Wurzer |
Mr. David M. Wurzer, CPA, serves as an Independent Director of Strategic Diagnotics Inc., since February 2010. Since 2009, Mr. Wurzer has served as Managing Director, Investments at Connecticut Innovations (CI), the State’s “venture capital arm.” He is responsible for sourcing and analyzing investment opportunities, CI investments in entrepreneurial high-tech ventures and advising portfolio companies. Prior to joining Connecticut Innovations, Mr. Wurzer most recently served as Executive Vice President, Treasurer and Chief Financial Officer of CuraGen Corporation, a biopharmaceutical development company, from September 1997 through December 2007. He has over 30 years of financial experience with growth-oriented companies, including direct involvement with raising capital, strategic transactions and mergers & acquisitions, for both start-up companies and publicly-held entities. Mr. Wurzer serves on the boards of Axerion Therapeutics, CyVek, NovaTract, Post-n-Track, , Thetis Pharmaceuticals, DUSA Pharmaceuticals and Response Genetics. Mr. Wurzer holds a BBA degree in Accountancy from the University of Notre Dame. |
Wayne Yetter |
Mr. Wayne P. Yetter serves as an Independent Director of Strategic Diagnotics Inc., since May 2010. In October 2009, Mr. Yetter became Chief Executive Officer of ProActive for Patients Media, Inc., an early investment stage company providing a physician-to-patient messaging system to increase patient adherence to medication therapies. Since October 2010, he serves only as the company’s Chairman. Mr. Yetter served as Chief Executive Officer of Verispan LLC, a joint venture of McKesson Corp. and Quintiles Transnational, a provider of healthcare information and marketing services to the pharmaceutical industry, from September 2005 to August 2008 when the company was acquired by SDI Health. Mr. Yetter had a 30 year career in the pharmaceutical industry and held executive positions at Pfizer, Merck, Astra-Merck (now AstraZeneca) and Novartis. His roles included Vice President, Marketing Operations (global) and Vice President, Far East and Pacific at Merck, founding Chief Executive Officer of Astra-Merck, and President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, the US division of Novartis AG. He also served as Chief Operating Officer of IMS Health, a market research data company from 1999 until 2000, when he became Chairman and Chief Executive Officer of Synavant, Inc. (a Nasdaq listed spin-out of IMS). Synavant was acquired by Dendrite International in 2003. Mr. Yetter currently serves as a director of EpiCept Corporation, InfuSystem Holdings, Inc., and NuPathe Inc., where he is Chairman. Previously, he served as Chairman of Noven Pharmaceuticals, Chairman of Transkaryotic Therapies, Lead Independent Director of Matria Healthcare (each of these companies was acquired) and as a director of Synvista Therapeutics, Inc. He also served on the Executive Committee of PhRMA, the pharmaceutical industry association, from 1997-1999. Mr. Yetter holds a B.A. in Biology from Wilkes University and received an M.B.A from Bryant University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Thomas Bologna |
-- |
Francis DiNuzzo |
574,506 |
Kevin Bratton |
359,003 |
Steven Becker |
-- |
C. Geoffrey Davis |
-- |
Richard van den Broek |
-- |
Stephen Waechter |
-- |
David Wurzer |
-- |
Wayne Yetter |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Thomas Bologna |
0 | 0 |
Francis DiNuzzo |
0 | 0 |
Kevin Bratton |
0 | 0 |
Steven Becker |
0 | 0 |
C. Geoffrey Davis |
0 | 0 |
Richard van den Broek |
0 | 0 |
Stephen Waechter |
0 | 0 |
David Wurzer |
0 | 0 |
Wayne Yetter |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
DINUZZO FRANCIS M |
23,812 | $1.05 |
BRATTON KEVIN J |
3,175 | $1.05 |
BRATTON KEVIN J |
10,000 | $1.05 |
DINUZZO FRANCIS M |
75,000 | $0.00 |
BECKER DRAPKIN MANAGEMENT L P |
706,834 | $1.18 |
BECKER DRAPKIN MANAGEMENT L P |
97,666 | $1.18 |
LINDPAINTNER KLAUS |
75,000 | $0.00 |
VAN DEN BROEK RICHARD A |
2,500 | $0.00 |
DAVIS CLAUDE GEOFFREY |
2,500 | $0.00 |
YETTER WAYNE P |
2,500 | $0.00 |
WAECHTER STEPHEN L |
2,500 | $0.00 |
BECKER DRAPKIN MANAGEMENT L P |
2,500 | $0.00 |
WURZER DAVID M |
2,500 | $0.00 |
BOLOGNA THOMAS A |
2,500 | $0.00 |
BECKER DRAPKIN MANAGEMENT L P |
14,127 | $1.94 |
BECKER DRAPKIN MANAGEMENT L P |
2,073 | $1.94 |
BECKER DRAPKIN MANAGEMENT L P |
601 | $1.81 |
BECKER DRAPKIN MANAGEMENT L P |
4,099 | $1.81 |
BECKER DRAPKIN MANAGEMENT L P |
22,169 | $1.85 |
BECKER DRAPKIN MANAGEMENT L P |
151,031 | $1.85 |
BOLOGNA THOMAS A |
2,500 | $2.10 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
